Psychiatrists Deny the Harm of Antidepressants for the Fetus

What happened to "do not harm"

Please read this important article by Dr. Peter C. Gøtzsche.

---

In 23 August 2025, award-winning science journalist Robert Whitaker, founder of the evidence-based Mad in America website, published a very important article:

”Not even the unborn are safe from psychiatric harm: Medical organizations and the media dismiss the large body of research telling of fetal harm from exposure to antidepressants during pregnancy.”

I summarize here Bob’s detailed article, adding my own thoughts and explanations about the issues.

On July 21, the FDA convened a panel on antidepressants in pregnancy, with a focus on possible harms to the fetus from exposure to the drugs.

The panelists’ brief presentations, and their plea for informed consent, did not sit well with medical organizations. They issued statements denouncing the panel as biased and misinformed; declared that the evidence showed that SSRIs and SNRIs are effective and safe treatments for prenatal depression; and claimed that the real concern was untreated depression. Major media echoed uncritically this flawed and erroneous expert consensus in their reporting on the panel.

The professional organizations betrayed the public’s right to know. They were putting their guild interests – protecting their prescribing practices and belief in the efficacy and lack of harms of antidepressants – ahead of their duty to provide an honest basis for informed consent. As detailed below, they misled the media, and the media in turn misled the public, in both cases very seriously so.

One of the panelists, Michael Levin, concluded that since serotonin is important for embryonic development, “manipulating its use by cells with SSRIs is very, very likely to cause certain kinds of defects.”

Animal experiments have proved him right. Fetal exposure to SSRIs leads to altered brain development, numerous risks to fetal health, and deficits in behavior after birth. At birth, fetal SSRI exposure in rodents is associated with low birth weight, persistent pulmonary hypertension, increased risk of cardiomyopathy, and increased postnatal mortality. After birth, such exposure is associated with delayed motor development, reduced pain sensitivity, disrupted juvenile play, fear of new things, and a higher vulnerability of affective disorders (such as anhedonia-like behavior). These behaviors are regarded as signs of anxiety and depression in animals.

With the animal studies showing also an increased risk for miscarriage, pre-term birth, and congenital malformations, the first wave of studies in humans focused on these concerns, in addition to low birth weight and persistent pulmonary hypertension. This research produced an abundance of findings that the risk of such adverse events is elevated with fetal exposure to SSRIs in comparison to healthy controls.

A fair number of studies tell of how in utero exposure to SSRIs alters brain development in humans and lead to other harms. For example, a study by Kaiser Permanente of Northern California of 82,170 pregnant women showed that if the depression was treated with counseling, the risk of a pre-term delivery was reduced by 18%, whereas treatment with an antidepressant increased it by 31%. In both cases, there was a dose-response relationship.

Another harm is the neonatal abstinence syndrome, which is common, e.g. it occurred in 30% of 60 newborns exposed to SSRIs in utero. Researchers have published an extensive list of abstinence symptoms, which includes jitteriness, poor muscle tone, weak cry, abnormal crying, respiratory distress, seizure, abnormal behavior, sleep abnormalities, poor feeding, vomiting, uncoordinated sucking, and lethargy. In a study using the World Health Organization’s database for adverse drug effects, researchers classified 84% of the reported abstinence symptoms as serious.

The Doubt Industry at Work

The rodent studies, which were not confounded, clearly showed how fetal exposure to SSRIs regularly leads to maladaptive adult rodents. Correspondingly, in comparison with healthy controls, studies of children exposed in utero to SSRIs show an elevated risk of getting diagnosed with ADHD, autism spectrum disorder, and affective disorders.

In a 2025 study, one of the FDA panelists, Jay Gingrich, and colleagues reported that prenatal exposure to SSRIs leads to a hyperactive amygdala both in mice and humans, which made both species more fearful and depressed as adolescents. Maternal depression could not explain these effects. Gingrich said at the FDA hearing that “these kids look pretty normal throughout early childhood, and then when they hit adolescence, their rates of depression really started to go up, which is what we see in our mouse studies.”

Bob Whitaker explains that studies in humans have produced inconsistent results. This is not surprising. When research results are threatening for a profession, researchers with guild or financial conflicts of interest always produce an avalanche of substandard studies casting doubt on the issues or denying them.

Maternal depression is known to confer developmental risks on children, and these researchers have therefore sought to account for this confounding factor by using statistical adjustments. Statistical adjustments are highly bias-prone, and in many of the studies Bob reviewed, the authors had not described their approach in sufficient detail nor whether the factors they controlled for had been published in a protocol before they looked at the data. Such studies can therefore be “torture your data till they confess” exercises.

A commonly used adjustment method is logistic regression, but what is little known is that the more baseline variables we include in a logistic regression, the further we are likely to get from the truth. This was documented in an excellent PhD thesis.

The Howl of Outrage

The same day the FDA had its panel meeting, or a couple of days later, leading medical organizations spread seriously misleading information.

The American Psychiatric Association wrote to the FDA that it was “alarmed and concerned by the misinterpretations and unbalanced viewpoints shared by several of the panelists…This propagation of biased interpretations at a time when suicide is a leading cause of maternal death within the first postpartum year could seriously hinder maternal mental health care. The inaccurate interpretation of data, and the use of opinion, rather than the years of research on antidepressant medications, will exacerbate stigma and deter pregnant individuals from seeking necessary care.”

The American College of Obstetricians and Gynecologists stated that the panel was “alarmingly unbalanced” and did not adequately acknowledge the harms of untreated mood disorders in pregnancy. They claimed that SSRIs in pregnancy are a critical tool in preventing the potentially devastating effects of untreated anxiety and depression.

They also claimed that “Robust evidence has shown that SSRIs are safe in pregnancy and that most do not increase the risk of birth defects. However, untreated depression in pregnancy can put our patients at risk for substance use, preterm birth, preeclampsia, limited engagement in medical care and self-care, low birth weight, impaired attachment with their infant, and even suicide…Unfortunately, the many outlandish and unfounded claims made by the panelists regarding SSRIs will only serve to incite fear and cause patients to come to false conclusions that could prevent them from getting the treatment they need.”

The Society for Maternal-Fetal Medicine stated they were “alarmed by the unsubstantiated and inaccurate claims made by FDA panelists concerning maternal depression and the use of SSRI antidepressants during pregnancy” and strongly supported the use of SSRIs.

They claimed that “Untreated or undertreated depression during pregnancy carries health risks, such as suicide, preterm birth, preeclampsia, and low birth weight…the available data consistently show that SSRI use during pregnancy is not associated with congenital anomalies, fetal growth problems, or long-term developmental problems.”

The National Curriculum in Reproductive Psychiatry was deeply concerned that some panelists “presented misleading or stigmatizing information about psychiatric treatment during pregnancy, undermined the scientific consensus, and failed to appropriately center the well-being of pregnant individuals.”

As shown in Whitaker’s article, virtually all statements were false, but they were propagated and enforced in major media, which did not investigate the issues at all.

The Los Angeles Times wrote that the panel spread misinformation about the drugs’ use in pregnancy and that healthcare providers had said that the risks of not treating depression in pregnancy far outweigh those of SSRIs.

The New York Times wrote that the panel was alarmingly biased against antidepressant use and did not adequately acknowledge the harms of untreated perinatal mood disorders in pregnancy.

NBC News accused the panel of promoting misinformation, “according to several psychiatrists who tuned into the meeting.”

National Public Radio talked about misinformation alarming doctors and claimed that

Well-controlled studies had not found the risks highlighted by the FDA panel.

Total Moral Meltdown

Those who spread misinformation were professional organizations riddled with conflicts of interest and – to paraphrase Lenin – their useful idiots among journalists.

There is nothing that hurts like the truth about healthcare. For the unborn child, fetal exposure to SSRIs only provides a tally of harms. Adam Urato, in his remarks at the FDA hearing, put it into a haunting perspective: “Never before in human history have we chemically altered developing babies like this, especially the developing fetal brain, and this is happening without any real public warning. That must end.”

An earlier Mad in America report on prenatal screening for depression showed that task forces set up in the UK, Canada, and the US all struggled to find evidence that screening plus treatment with antidepressants provided any benefit to the mother.

I describe in my freely available books, with numerous references to solid science, what the facts are:

As explained by psychiatrist Joanna Moncrieff at the FDA meeting, meta-analyses of placebo-controlled trials have consistently shown that the benefit of treating depression with antidepressants is so small that it lacks clinical relevance. It is therefore impossible that the risks of not treating depression in pregnancy “far outweigh those of SSRIs.”

Antidepressants double the risk of suicide. Depression in pregnancy should therefore be treated with psychotherapy, which will not harm the fetus. The panel members spoke of treating depression with non-drug alternatives but the media did not find this essential information important. In the absurd world of psychiatry, unfortunately, “treatment” is synonymous with drugs.

All the claims above about the wonders antidepressants can achieve for the mother and the newborn are wrong.

Antidepressants are being increasingly used in children and adolescents, although they drive some of them to commit suicide and don’t work for them.

Even the unborn are being harmed on a large scale. Will this madness ever stop?

---

---

---

This article was first published at the Brownstone Institute.

The author: Peter C. Gøtzsche

Dr. Peter Gøtzsche co-founded the Cochrane Collaboration, once considered the world’s preeminent independent medical research organization. In 2010 Gøtzsche was named Professor of Clinical Research Design and Analysis at the University of Copenhagen. Gøtzsche has published about a 100 papers in the “big five” medical journals (JAMA, Lancet, New England Journal of Medicine, British Medical Journal, and Annals of Internal Medicine). Gøtzsche has also authored books on medical issues including Deadly Medicines and Organized Crime.